

MANAGEMENT

Mel Sorensen, MD
President and CEO

Lance Leopold, MD
Chief Medical Officer
VP, Clinical Development

Joel F. Sussman, CPA
Chief Financial Officer

Ming Guo, PhD
VP, Manufacturing
General Manager, Ascenta Shanghai
R&D Center

Dajun Yang, MD, PhD
Head of Research

Shaomeng Wang, PhD
Chief Scientific Advisor

BOARD OF DIRECTORS

Eckard Weber, MD
Chairman, Domain Associates

Lou Bock
Scale Venture Partners


Marc Lippman, MD
Professor and Chair, Department of
Medicine at the University of Miami

Mike Powell, PhD
Sofinnova Ventures

Norman Selby
Perseus LLC

Drew Senyei, MD
Enterprise Partners

Mel Sorensen, MD
Ascenta President and CEO



Ascenta Therapeutics, Inc. is a privately-held, clinical-stage biopharmaceutical company that discovers and develops new medicines for the treatment of cancer.

Licensed from both the National Institutes of Health and the laboratory of Dr. Shaomeng Wang at the University of Michigan, Ascenta's technology is focused on discovering molecules that target proteins responsible for prolonging cancer cell survival.

Scientific Approach FINDING KEYS TO UNLOCK APOPTOSIS

Multicellular organisms use apoptosis, or programmed cell death, to eliminate abnormal or unwanted cells. As a result of accumulated mutations, all cancer cells fail to execute an apoptotic program, allowing them to live indefinitely and grow uncontrollably. In fact, the breakdown of the cellular apoptosis regulatory machinery is a hallmark of cancer. Most current cancer therapies, including chemotherapeutic agents, radiation, and immunotherapy, work by inducing apoptosis in cancer cells. However, because the normal apoptotic pathways are defective, many cancer cells are resistant or develop resistance to these agents. Accordingly, a promising new direction for drug development involves targeting apoptotic proteins directly to induce cell death and/or reduce resistance to other treatments.

Ascenta's pipeline now includes several potential anticancer therapies that target different parts of the apoptotic pathway to inhibit the proliferation of abnormal cells and reestablish the cell death program (pipeline details on reverse page).

DISCOVERY	PRECLINICAL	PHASE I		PHASE II		PHASE III
		IND		Exploratory	Confirmatory	NDA
AT-101: Oral pan-Bcl-2 Inhibitor						
Prostate (HRPC-1L) Taxotere®-Eligible Patients						With Taxotere®
Prostate (HRPC-2L) Taxotere®-Refractory Patients						With Taxotere®
Lung (NSCLC-2L) Taxotere®-Eligible Patients						With Taxotere®
Lung (SCLC) 1st & 2nd-line Chemo combinations						
Glioma (GBM) with Radiation & Chemotherapy						
B-Cell Malignancies (NHL & CLL) with Chemo/Biologics						
Prostate (HSPC) Hormone-Sensitive Patients						
Esophageal with Radiation & Chemotherapy						
AT-406: Oral multi-IAP Inhibitor						
Cancers						
Oral Inhibitor of HDM2-p53						
Cancers						

Investors

Ascenta's investors include Domain Associates, Enterprise Partners, Pac-Link, Perseus LLC, Scale Venture Partners, Sofinnova Ventures, and US Venture Partners.





AT-101: Pan-Bcl-2 Inhibitor

AT-101 is an orally-active, pan-Bcl-2 inhibitor (including Bcl-2, Bcl-xL, Bcl-w, and Mcl-1 inhibition) that has been shown to induce apoptosis directly by operating as a BH3 mimetic and indirectly as an independent upregulator of Noxa and Puma. By blocking the binding of Bcl-2 family members with proapoptotic proteins and upregulating specific proapoptotic factors, AT-101 lowers the threshold for cancer cells to undergo apoptosis in various tumor types.

In Phase I and Phase II trials, AT-101 has demonstrated single-agent cytoreductive activity in several cancers, including chronic lymphocytic leukemia (CLL), non-Hodgkins lymphoma (NHL), and prostate cancer. Phase II combination trials are ongoing in several cancers, including hormone-refractory prostate cancer and non-small cell lung cancer (with Taxotere[®]), B-cell malignancies (with Rituxan[®]), small cell lung cancer (with Hycamtin[®]), glioma (with Temodar[®], +/- chemoradiotherapy [XRT]) and esophageal cancer (with docetaxel, 5-fluorouracil and XRT). Initial findings from an ongoing open-label, multi-center study of AT-101 in combination with docetaxel and prednisone in patients with hormone-refractory prostate cancer (HRPC) demonstrated that AT-101 can be safely administered and produces clinical responses, based on both PSA and tumor shrinkage (RECIST) criteria.

AT-406: Multi-IAP Inhibitor

AT-406 is an orally-active, small molecule drug designed to promote programmed cell death (apoptosis) in tumor cells by blocking the activity of "inhibitors of apoptosis proteins" or IAPs (including XIAP, c-IAP1, c-IAP2, and ML-IAP) to create conditions in which apoptosis can proceed. As such, AT-406 is considered a multi-IAP antagonist. IAPs are key components of the complex cascade of protein signaling that activates enzymes called caspases to initiate the breakdown of the cancer cell. AT-406 is thought to mimic the activity of Smac (second mitochondria-derived activator of caspases) by binding to XIAP and preventing it from inhibiting caspase activation. Upon binding to cIAP1 and cIAP2, AT-406 induces rapid degradation of these proteins and promotes apoptosis through activation of the death-receptor complex and caspase 8.

AT-406 is in late-stage preclinical development and has demonstrated strong single-agent antitumor activity in multiple xenograft models of human cancer, including breast cancer, pancreatic cancer, prostate cancer, and lung cancer. AT-406 has also been shown to work synergistically with conventional chemotherapeutic and targeted agents (such as TRAIL and tyrosine kinase inhibitors) in preclinical tumor models. The next key milestone will be filing an IND application with the FDA.

HDM2 Inhibitor

Ascenta's third program involves inhibition of HDM2 (Human Double Minute 2), a protein that regulates the activity of another important component of the apoptotic pathway, the p53 tumor suppressor protein. Ascenta has a potent, non-peptide small molecule that restores p53 function in cancer cells with wild-type (unmutated) p53. This orally-active agent is in late-stage preclinical development.



ASCENTA CORPORATE HEADQUARTERS

101 Lindenwood Drive
Suite 405
Malvern, PA 19355
TEL 610 408 0301
FAX 610 725 1515

R&D PRECLINICAL FACILITY

Pudong Shangjiang Hi-Tech Park
Shanghai, P.R. China